1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Will Biosimilar Competition And Product-Hopping Save Regeneron’s Eylea Or Cancel Each Other Out?

 
• By Dean Rudge

Biosimilar entrants look to help protect Regeneron’s currently marketed form of Eylea from the US’s new price negotiation law. But it likely hinges on how CMS views the company’s product-hopping plan.

Joe Biden, Democratic Party (Ron Adar/Shutterstock.com)
The IRA, signed by the Biden administration, created the Medicare price negotiation system. • Source: Shutterstock

Biosimilar entrants are likely to protect Regeneron Pharmaceuticals, Inc.’s Eylea (aflibercept) from price negotiations under the Inflation Reduction Act, though the protection may hinge in part on how successful Regeneron is at switching patients to a planned high-dose formulation of the biologic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics